---
figid: PMC5000709__ijms-17-01312-g002
figtitle: Kallistatin inhibits angiogenesis and inflammation through blocking VEGF
  signaling and NADPH oxidase activity
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Bos taurus
- Gallus gallus
- Lareunionomyces loeiensis
pmcid: PMC5000709
filename: ijms-17-01312-g002.jpg
figlink: /pmc/articles/PMC5000709/figure/ijms-17-01312-f002/
number: F2
caption: 'Kallistatin inhibits angiogenesis and inflammation through blocking VEGF
  signaling and NADPH oxidase activity. Kallistatin inhibits VEGF signaling through
  VEGFR-2 by its heparin-binding domain. VEGF-VEGFR signaling through PI3K-Akt pathway;
  the p38 MAPK pathway; and the PLC pathway leads to ROS/NO production, apoptosis,
  gene expression, cell migration, cell proliferation and inflammation. All of which
  are involved in angiogenesis. Kallistatin also directly inhibits NADPH oxidase activity
  and attenuates ROS production. NADPH oxidase is a complex consisting of several
  components. NADPH activity and VEGF-A/VEGFR-2 signaling have close interaction that
  is able to induce or activate many proangiogenic factors, such as MCP-1, VEGF, NF-κB,
  IL-8, VCAM-1, VE-cadherin and HIF1α in endothelial cells. Abbreviations: Akt—also
  known as protein kinase B—PKB; DAG—diacylglycerol; ERK—extracellular signal-regulated
  kinase; eNOS—endothelial nitric oxide synthase; HIF1α—hypoxia induced factor 1 alpha;
  IκB—inhibitor of nuclear factor κB; IL-8—interleukin-8; MAPK/MEK—mitogen activated
  protein kinase; MCP-1—monocyte chemoattractant protein-1; NADPH—nicotinamide adenine
  dinucleotide phosphate; NF-κB—nuclear factor κ B; NO—nitric oxide; PDK1/2—3-phosphoinositide
  dependent protein kinase 1 and 2; PI3K—phosphatidylinositol-3 kinase; PIP2—phosphatidylinositol
  4,5-bisphosphate; PKC—protein kinase C; PLC—phospholipase C; PTP—protein tyrosine
  phosphatase; Rac1—small GTPase; ROS—reactive oxygen species; SOD—manganese superoxide
  dismutase; Src—non-receptor tyrosine kinase; VCAM-1—vascular cell adhesion molecule-1;
  VE—vascular endothelial; VEGF-A—vascular endothelial growth factor-A; VEGFR-2—VEGF
  receptor-2. The blue arrow lines indicate promotional activity; the red stop lines
  indicate inhibiting activity.'
papertitle: The Potential Role of Kallistatin in the Development of Abdominal Aortic
  Aneurysm.
reftext: Jiaze Li, et al. Int J Mol Sci. 2016 Aug;17(8):1312.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.960331
figid_alias: PMC5000709__F2
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
- Gallus gallus
- Rattus norvegicus
- Bos taurus
redirect_from: /figures/PMC5000709__F2
ndex: e26028af-dede-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5000709__ijms-17-01312-g002.html
  '@type': Dataset
  description: 'Kallistatin inhibits angiogenesis and inflammation through blocking
    VEGF signaling and NADPH oxidase activity. Kallistatin inhibits VEGF signaling
    through VEGFR-2 by its heparin-binding domain. VEGF-VEGFR signaling through PI3K-Akt
    pathway; the p38 MAPK pathway; and the PLC pathway leads to ROS/NO production,
    apoptosis, gene expression, cell migration, cell proliferation and inflammation.
    All of which are involved in angiogenesis. Kallistatin also directly inhibits
    NADPH oxidase activity and attenuates ROS production. NADPH oxidase is a complex
    consisting of several components. NADPH activity and VEGF-A/VEGFR-2 signaling
    have close interaction that is able to induce or activate many proangiogenic factors,
    such as MCP-1, VEGF, NF-κB, IL-8, VCAM-1, VE-cadherin and HIF1α in endothelial
    cells. Abbreviations: Akt—also known as protein kinase B—PKB; DAG—diacylglycerol;
    ERK—extracellular signal-regulated kinase; eNOS—endothelial nitric oxide synthase;
    HIF1α—hypoxia induced factor 1 alpha; IκB—inhibitor of nuclear factor κB; IL-8—interleukin-8;
    MAPK/MEK—mitogen activated protein kinase; MCP-1—monocyte chemoattractant protein-1;
    NADPH—nicotinamide adenine dinucleotide phosphate; NF-κB—nuclear factor κ B; NO—nitric
    oxide; PDK1/2—3-phosphoinositide dependent protein kinase 1 and 2; PI3K—phosphatidylinositol-3
    kinase; PIP2—phosphatidylinositol 4,5-bisphosphate; PKC—protein kinase C; PLC—phospholipase
    C; PTP—protein tyrosine phosphatase; Rac1—small GTPase; ROS—reactive oxygen species;
    SOD—manganese superoxide dismutase; Src—non-receptor tyrosine kinase; VCAM-1—vascular
    cell adhesion molecule-1; VE—vascular endothelial; VEGF-A—vascular endothelial
    growth factor-A; VEGFR-2—VEGF receptor-2. The blue arrow lines indicate promotional
    activity; the red stop lines indicate inhibiting activity.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pdk1
  - Pdpk1
  - Pdk2
  - Src
  - Mfge8
  - Ruvbl2
  - Nsfl1c
  - Ncf1
  - Ncf2
  - Metap2
  - pk
  - Hspg2
  - Rac1
  - Akt1
  - Akt2
  - Crk
  - Grap2
  - Syp
  - Mapk14
  - Ahsa1
  - Slc25a3
  - Ptpru
  - Ptprs
  - Reg1
  - Reg2
  - Nos3
  - Mdk
  - Casp3
  - Nfkb1
  - Ephb2
  - Mapk1
  - Decr1
  - Dync1h1
  - Vegfa
  - SERPINA4
  - PDK1
  - PDPK1
  - PDK2
  - SRC
  - FGR
  - FYN
  - YES1
  - ING1
  - PLEK
  - CLEC11A
  - AKAP13
  - NSFL1C
  - H3P37
  - NCF1
  - NCF2
  - CD33
  - STXBP1
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - RAC1
  - RNASE1
  - AKT1
  - AKT2
  - AKT3
  - PTK2B
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK3
  - MAPK8
  - MAPK9
  - MAPK10
  - SLC25A3
  - REG1A
  - PTPRU
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - SOD1
  - SOD2
  - SOD3
  - NOS3
  - ENO4
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - NFKB1
  - EPHB2
  - DECR1
  - DYNC1H1
  - CHP1
  - PHB2
  - VEGFA
  - CASP3
  - P22
  - Ddx39b
  - Cyba
  - Rnase1l1
  - Ptpn1
  - Ptpn13
  - Prkcg
  - Ephb1
  - METAP2
  - REG3A
  - Cancer
---
